About Health Insights

Tuesday, July 1, 2025

Public Oncology Biotechs Get Bought Most in Commercial Launch Phase or in Phase 1 / 2 Stage

https://www.stifel.com/newsletters/investmentbanking/bal/marketing/healthcare/biopharma_timopler/2025/StifelOncologyUpdate_June2025.pdf

Newer Post Older Post Home

China-origin assets accounted for an even larger share of big pharma licensing in Q1 2026

https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q1-2026.pdf

Weight loss dominates the GLP-1 narrative

https://s3.amazonaws.com/media.mediapost.com/uploads/DENTSU_GL1_February_2025.pdf
Potential Launch Timeline for New GLP-1 Therapies and Combinations: Competition to Novo and Lilly Begins in 2026

https://assets.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blt79266ca5d3a390c1/Obesity_Drug_Market_Report.pdf
Trailblazers in AI-Enhanced Drug Development: Exploring Key Startups and Their Innovations

https://www.aranca.com/assets/docs/AI-Revolution-in-Drug-Industry-Transforming-R&D-and-Financial-Growth.pdf

Search This Blog

Simple theme. Powered by Blogger.